News – Page 979 – Endpoints News

Supernus touts ADHD Phase III data, but results appear to fall short of expectations

7 years ago

Disgraced VC Steven Burrill heads to prison with 30-month sentence for fraud, tax evasion

7 years ago

Seattle’s Impel NeuroPharma bags $67.5M crossover raise for a round of new drug/device CNS clinical trials

7 years ago

While we wait for NASH data, Genfit reports positive elafibranor data in PBC patients

7 years ago

AbbVie’s troubled $10B Rova-T cancer drug program takes a sudden turn toward the cliff

7 years ago

Novartis’ partners at Conatus have another NASH setback to confess today

7 years ago

UK sets up vaccines centre as Brexit looms; Shanghai's Elpiscience bags $35M in Series B

7 years ago

Troubled MiMedx axes a quarter of its workforce in the wake of a C-suite purge

7 years ago

In the wake of deep R&D cuts, Bayer flags safety concerns for a top PhIII drug

7 years ago

Mereo reverse merges with a flailing OncoMed and preps for a back flip onto Nasdaq

7 years ago

Forget Hong Kong, Grail is now going for a 2019 IPO in the US — Bloomberg

7 years ago

A last-ditch effort to derail Takeda’s $62B Shire buyout goes down in flames

7 years ago

What do Martin Shkreli, Gilead and Takeda have in common? They all figure prominently in the new top-20 list of the ...

7 years ago

FDA issues draft guidance on NASH drug development

7 years ago

Roswell Park spinout raises $35M from Chinese investors to pursue one-two punch for adoptive T cell therapy

7 years ago

Gilead's HIV drug Descovy wins China's endorsement; Revance investors smile as frown lines drug succeeds pivotal ...

7 years ago

Bispecifics vs CAR-T: Analysts select the big winners — and losers — at #ASH18's biggest ever datapalooza

7 years ago

The Great Pharma Brexit? An Endpoints News snap poll finds most life sciences insiders predicting a debacle for the ...

7 years ago

Vanda's PhII data offer hope for gastroparesis patients who have seen no new treatments in decades

7 years ago

Novartis plots to retain hives patients with monoclonal antibody that outshines Xolair

7 years ago

#ASH18: Can Amgen break through the BCMA CAR-T line and take a BiTE of the multiple myeloma market? It won't be quick ...

7 years ago

#ASH18: Allogene ticks off a high CR rate for updated off-the-shelf CAR-T pioneer. But getting just the right kind of ...

7 years ago

#ASH18: Legend Biotech — allied with J&J now — continues to wow the crowd with their BCMA CAR-T update. What will ...

7 years ago

#ASH18: BeiGene works to bust through the checkpoint crowd with a pivotal readout that proves its PD-1 is better than ...

7 years ago

First page Previous page 976 977 978979980 981 982 Next page Last page